Skip to main content

Ardelyx Announces Key Leadership Transitions

Tipranks - Tipranks - Thu Dec 18, 2025

Claim 50% Off TipRanks Premium and Invest with Confidence

Ardelyx ( (ARDX) ) has issued an update.

Ardelyx, Inc., a company operating in the pharmaceutical or healthcare sector, announced leadership transitions involving two key executives. On December 17, 2025, Elizabeth Grammer, Chief Legal and Administrative Officer, informed the company of her resignation effective December 31, 2025. Following this, she will continue to serve as General Counsel until a successor is appointed and later transition to a Senior Advisor role for two years. Her transition is structured under a detailed agreement that includes salary continuation, bonuses, and other benefits tailored to her role during the advisory period. Additionally, Edward Conner, M.D., Chief Medical Officer, also announced his resignation for personal reasons, effective December 31, 2025. Dr. Laura Williams will temporarily take over as interim Chief Medical Officer, ensuring continuity in the company’s clinical development programs.

The most recent analyst rating on (ARDX) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Ardelyx stock, see the ARDX Stock Forecast page.

Spark’s Take on ARDX Stock

According to Spark, TipRanks’ AI Analyst, ARDX is a Neutral.

Ardelyx’s strong revenue growth and strategic initiatives are promising, but profitability challenges and reliance on debt weigh on the score. Technical indicators suggest potential for a rebound, while the earnings call provides a positive outlook for future growth.

To see Spark’s full report on ARDX stock, click here.

More about Ardelyx

Average Trading Volume: 3,434,917

Technical Sentiment Signal: Buy

Current Market Cap: $1.46B

For a thorough assessment of ARDX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).